A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis  

作　　者：Corey Saraceni John Birk 

机构地区：[1]University of Connecticut School of Medicine,Department of Medicine,Division of Gastroenterology and Hepatology,Farmington,CT,USA

出　　处：《Journal of Clinical and Translational Hepatology》2021年第3期409-418,共10页临床与转化肝病杂志（英文版）

摘　　要：Despite the advances in therapy,hepatitis B virus(HBV)and hepatitis C virus(HCV)still represent a significant global health burden,both as major causes of cirrhosis,hepatocellular carcinoma,and death worldwide.HBV is capable of incorporating its covalently closed circular DNA into the host cell’s hepatocyte genome,making it rather difficult to eradicate its chronic stage.Successful viral clearance depends on the complex interactions between the virus and host’s innate and adaptive immune response.One encouraging fact on hepatitis B is the development and effective distribution of the HBV vaccine.This has significantly reduced the spread of this virus.HCV is a RNA virus with high mutagenic capacity,thus enabling it to evade the immune system and have a high rate of chronic progression.High levels of HCV heterogeneity and its mutagenic capacity have made it difficult to create an effective vaccine.The recent advent of direct acting antivirals has ushered in a new era in hepatitis C therapy.Sustained virologic response is achieved with DAAs in 85–99%of cases.However,this still leads to a large population of treatment failures,so further advances in therapy are still needed.This article reviews the immunopathogenesis of HBV and HCV,their properties contributing to host immune system avoidance,chronic disease progression,vaccine efficacy and limitations,as well as treatment options and common pitfalls of said therapy.

关 键 词：Hepatitis B immunopathogenesis Hepatitis C immunopathogenesis 

分 类 号：R51[医药卫生—内科学]